How Innovative Bladder Cancer Treatments Can Help Overcome BCG Shortages

Public Health

How Innovative Bladder Cancer Treatments Can Help Overcome BCG Shortages

In those parts of the country where access to strains of BCG is limited, patient treatment regimens have emphasized proper use and rationing.

The Bacillus Calmette-Guerin (BCG) vaccine is the most common treatment doctors use to treat patients with non-muscle invasive bladder cancer (NIMBC).

Manufacturing restrictions placed on the production of BCG, predating the emergence of the novel coronavirus — coupled with the slow growth of mycobacteria — have made it difficult to produce BCG and sparked a need to explore alternative bladder cancer treatments.

The restrictions have impacted both production capability and production quality.

How Have BCG Shortages Impacted Access to Treatment?

Merck, the sole supplier of BCG in the U.S., plans to address supply shortages by starting construction on  a second BCG production facility this year to help increase supply, but it will take several years to complete the project, according to the American Urological Association.

Dr. Sam Chang, a chief surgical officer with Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discussed how BCG shortages have impacted access to treatment in a recent Urology Times interview.

"There are individuals within the same city (who) may have access to BCG, and (who) may not," he said. "It has affected patients in a sporadic fashion, where there hasn't been a clear source of, ‘OK, everybody's going to have a shortage. In fact, it is somewhat haphazard.’"

Currently, medical facilities have limited access to BCG, impacting the quality of patient care for the foreseeable future. In those parts of the country where access to strains of BCG is limited, patient treatment regimens have emphasized proper use and rationing, Chang said.

Innovative Bladder Cancer Treatments Are on The Rise

In August 2021, Keytruda, a type of immunotherapy, became the first treatment approved by the U.S. Food and Drug Administration in several years that's immediately available to help treat patients with frontline bladder cancer.

Keytruda is given to patients intravenously every six weeks. Forty percent of those patients who initially rejected BCG and then participated in the Keytruda  trials started seeing positive results within about three months after beginning treatment after their bodies had initially rejected the BCG vaccine, according to Chang.

With Keytruda still in its infancy, other researchers are conducting trials of their own, which include blending a combination of BCG in smaller amounts or for shorter durations, with a systematic immunotherapy agent that generates a more significant response, says Chang.

Other experimental therapies such as nadofaragene and vicineum are in production and have shown potential but have so far failed to meet FDA standards, said Chang.

BCG will always be the bladder cancer treatment standard that new treatments will be challenged to meet. New trials are being conducted every day, with many implementing the use of BCG. What’s needed now, according to Chang, is a set of comparative trials demonstrating an alternative treatment that is considered effective and most often used in addition to BCG to treat bladder cancer.        

More Urology Articles
‘Practical, Inexpensive, and Harmless’ Ways to Reduce Pain During Cystoscopy
Best Practices
A systematic review uncovers ways to reduce the pain of flexible cystoscopy without the use of drugs.
4 Reasons Urologists, Procurement Managers Would Switch to Single-Use Cystoscopes
Emerging Technologies
The authors of a May study investigated worldwide market readiness of single-use flexible cystoscopes through a survey of urologists and procurement managers in France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States.
More From Single-Use Endoscopy

Emerging Technologies

Physicians, researchers, and other industry professionals will gather in San Diego for Digestive Disease Week 2022 after the COVID-19 pandemic forced the event to go virtual each of the past two years.

5 Things Urologists Were Talking About at AUA 2022

Endoscopy Tech

Patient engagement and advancing diversity in urologic oncology were among the topics probed over three days in New Orleans as the American Urology Association held its annual meeting.

A Matter of Time: Shifting the Healthcare Paradigm With Single-Use

Emerging Technologies

At DeviceTalks Boston, med-tech executives talk of a day when single-use endoscopy is the standard of care and reusable endoscopes are “hanging in a museum.”